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The concept of the immunogenicity of an antigen is frequently encountered in the context of vaccine
development, an area of intense interest currently due to the emergence or re-emergence of infectious pathogens
with the potential for worldwide spread. However, the theoretical notion of immunogenicity as discussed in older
textbooks of immunology needs reconsideration due to advances in our understanding of immunologic responses.
Immunogenicity is a property that can either be a desirable attribute, for example in the generation of an effective
protective immunity against infectious pathogens or an undesirable trait, for example when it relates to novel
therapeutic compounds and drugs, where an immune response needs to be prevented or inhibited. In this Forum
Article, we aimed to revisit the issue of immunogenicity to discuss a series of simple questions relevant to the
concept that are frequently rephrased but incompletely resolved in the immunologic literature.
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A formal definition of immunogenicity can be stated as
“the ability of a molecule or substance to provoke an im-
mune response” or “the strength or magnitude of an im-
mune response” [1]. In this definition, the term “immune
response” refers to “an integrated systemic response to an
antigen (Ag), especially one mediated by lymphocytes and
involving recognition of Ags by specific antibodies (Abs)
or previously sensitized lymphocytes” [2]. As such, the def-
initions are uniquely indicative of the adaptive immune
system (that gives rise to adaptive immunity, vis a vis in-
nate immunity).
Adaptive immunity either relays innate immunity if it
not succeeded in completely clearing an infection by a
pathogen (thus serving as a second line of defense
against the invading or damaging agent) or is mobilized
in a straighter way when the body faces pathogens’ moi-
eties to which it has already developed tools (post nat-
ural or vaccine infection). For this line of defense to
succeed, certain conditions need to be satisfied: 1) in-
structions for engaging the non-self pathogen have to be* Correspondence: ogarraud@ints.fr
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unless otherwise stated.conveyed from innate immune cells to professional or
ad hoc Ag presenting cell (APCs); 2) a favorable envir-
onment has to be generated that facilitates cell recruit-
ment and growth, and inhibits apoptosis and attrition of
effector cells, not only by local tissues but also in drain-
ing lymphoid tissues such as lymph nodes to which the
pathogens are transported by specialized cells [3]. Adap-
tive immunity principally relies on stringently recognized
epitopes selected from a finite, albeit immense, library of
T and B lymphocyte receptors (TcRs, BcRs). In short, an
efficient adaptive immune response requires ligation of
an optimally matched epitope to a complementary TcR.
This process involves changes to the TcR that occur in
the expressing lymphocyte as it passes through the ger-
minal center (GC) of the draining lymph node. These
changes, in turn, alter T and B cell interactions, promot-
ing B cell maturation in the same GC via hypersomatic
mutations that occur in centroblasts within the GC dark
zone, and isotype commutation (in centrocytes in the
GC light zone) [4]. Cell to cell communication through
multiple adhesion sites and cytokine and chemokine ac-
tion through their respective receptors are essential for
this process, controlling the T and B cell migration and,
consequently, their terminal differentiation [4]. An opti-
mal response of this immunological reaction is the goal
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epitopes. Thus, immunogenicity is more or less the
property of an Ag that allows the efficient fulfillment of
each of the steps outlined above; if the Ag fails to trigger
any of these steps, the adaptive immune response is ei-
ther ineffectual or fails to develop. Steps of this process
that can be modeled in human immune cells through
ex vivo experiment or in animal models provide insights
into a number of critical determinants of the immuno-
genic properties of Ags.
In general, immunogenicity may not be a factor that is
a sine qua non for immunity to infection. Immunogen-
icity appears not to be a crucial factor or even a require-
ment for eliciting a robust response against pathogens
and, in certain circumstances, pathogen-derived mole-
cules, as it seems that low immunogenicity can be over-
come by other factors. Conversely, immunogenicity is
not a desirable property when the foreign molecule or
Ag needs to be tolerated and not recognized as a patho-
gen. Examples of such Ags include those derived from
allogeneic blood cells, transplanted hematopoietic cells,
homologous tissues or solid organs or therapeutic bio-
logics. In such situations it is often necessary to reduce
Immunogenicity using immunomodulating procedures
such as tolerization (in case of allergy, or unintended
immunization to biologics). In the case of infectious
pathogens, reduction in the immunogenicity of an Ag is
generally not a desired outcome unless there is concern
about cross-reacting epitopes that induce autoimmunity
or where immunopathology accounts for disease mani-
festations.. Interestingly, in such situations, there may
have to be a tradeoff between the reduction in immuno-
genicity and protective immune responses. This is often
the case with infections with intracellular pathogens such
as Mycobacterium tuberculosis Toxoplasma gondii, Plas-
modium spp., and Schistosoma spp., to cite a few [5].
The concept of immunogenicity is also connected inex-
tricably with the issue of immune memory. Immune mem-
ory, which can be generated in the central or peripheral
immune system, is a hallmark of adaptive immunity and is
one of the major outcomes of an effective, specific response
[4]. Indicators of effective immunity include the sustained
production of effector lymphocytes, and, conversely, the de-
velopment of tolerance. The immunogenicity of an Ag is
instrumental in directing Ag-specific lymphocytes to a ded-
icated response pathway. In general, the greater the im-
munogenicity of an Ag, the smaller the amount of Ag
required to elicit an immune response, the more robust the
recall responses (peripheral memory) and higher the affinity
of the epitope/target interaction. Thus, our understanding
of immunogenicity, as a property of an Ag, suggests that it
is crucial both for determining the initial immune response
to a given Ag as well as the strength and duration of the
adaptive immune response over the longer term.Unanswered questions regarding the
determinants of immunogenicity
For decades, there has been active debate about to the
determinants of immunogenicity in reviews and text-
books. A search on PubMed today yields a large number
of entries, but nearly all reviews discussing the factors
that determine antigenic immunogenicity are focused on
two aspects: 1) the requirements for development of im-
proved vaccines against resistant microbes, and 2) the
avoidance of unwanted immune response against bio-
logics and, particularly, against therapeutic monoclonal
Abs. This intense interest centers around a number of
questions regarding the nature of immunogenicity that
remain unanswered after more than 10 years of discus-
sion on the determinants of immunogenicity. These
questions can be simply stated as:
1. Why are some infectious pathogens weakly
immunogenic?
2. What is an immunogenic or major epitope?
3. What is optimal Ag presentation?
4. What is the optimal cellular environment for
facilitating and supporting Ag- reactive (previously
termed “Ag-specific”) T and B cells?
5. What drives isotype switching? Why is it necessary?
And what makes an Ab “protective”?
6. Why is a long term memory response less robust
when elicited by engineered peptides than by wild-type
pathogen-derived Ags?
Why are some infectious pathogens so poorly
immunogenic?
It is striking that although more than 130 years have
elapsed since the first engineered human vaccine for a
pathogen was successfully administered to a patient (and
near 220 years after the perhaps “first” vaccine by
Jenner); despite decades of research focused on identify-
ing protective vaccine candidates, there are, as yet, no
safe and protective vaccine for many infectious agents.
Undoubtedly, the complexity of many pathogens is a
major obstacle to success in this area of research. This is
reflected in the fact that no practical vaccines have been
developed against intracellular or extracellular parasites,
although a few examples of natural vaccines are trad-
itionally cited as successes, such as leishmanization for
cutaneous leishmaniasis [6]. While the non-protein part
of bacteria (especially sugars from the capsule and/or
the surface) may elicit Ab responses, those are infre-
quently neutralizing as opposed to agglutinating, and
they are not thought to originate from T-dependent B cell
responses [7,8]. In these situations, T cell-independent,
extrafollicular B cell responses tend to predominate with
low-affinity IgM responses and no memory responses. It
appears that only the peptides and toxins appear to be
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Mycobacteria are particularly interesting because one vac-
cine—Bacille Calmette-Guerin (BCG)—has been available
since the late 20’s (a result of 40 years of research), but in
the large clinical trials has been found to be insufficiently
protective against pulmonary tuberculosis in humans [9].
Despite concerted research for almost 80 years, little pro-
gress has been made with improvement of the immuno-
genicity of BCG.
In contrast, viruses present a different story. Most
antiviral vaccines are peptide- based, and likely as a con-
sequence, a number of these vaccines have been more
effective than those for bacterial and parasitic pathogens
mentioned above [10,11]. Indeed, the success of several
antiviral vaccines has raised the hope of, and in one case
(variola), even succeeded in eradicating certain viral in-
fections. Nevertheless, the same strategy that succeeded
in developing effective vaccines for some viruses has failed
for are many viral infections. Examples of unsuccessful
vaccines include those for HIV, EBV, HSV, Dengue virus,
and other emerging viral pathogens [12]. Nucleic acid-
based vaccines have also been disappointing, not only for
cancer and autoimmune conditions, but also for infectious
diseases, for example with HIV [13]. In the case of prion-
associated diseases, despite the peptide nature of prions,
not only is there little progress for development of vac-
cines, even Ab-based tools for diagnosis have not been
achieved [14]. Thus, it appears that the abundance of non-
protein Ags among infectious pathogens is not the only
factor that limits immunogenicity.
What is an immunogenic versus a major epitope?
How does this relate to the issue of antigenic
competition?
Although there has been a remarkable lack of success in
the development of vaccines against some of the major
infectious pathogens, there are some salutary lessons
learned from research in vaccine engineering. Repeated
failures of selected vaccine candidates, selected on ap-
parently sound immunological rationales raises ques-
tions about the nature of epitopes that induce sustained
T- or B-cell responses versus their capacity to induce
functionally protective effectors. Some of those epitopes
are undoubtedly useful as diagnostic tools, but disap-
point as vaccine candidates. As Ags, these molecules do
possess qualities that would be predicted to confer im-
munogenicity. These epitopes are frequently expressed
abundantly on the surface of infectious pathogens (often
as components of envelope structures) and are com-
posed of simple repeated motifs. Their biochemical com-
position (alignment and/or folding of amino acids [AA])
largely explains their capacity to stimulate T cells (via
their TcR) and B cells (via their BcR or by cognate inter-
actions with T cells). The strong immune responsesresulting from stimulation by these Ags also implies that
the major histocompatilibity complex (MHC) can effi-
ciently bind those peptides and present them to reactive
TcRs. Alternatively, or additionally, a large number of
MHC molecules may be able to bind those peptides, im-
plying a weak MHC restriction. However, when one tries
to immunize animals with such antigenic peptides for
selection of vaccine candidates or to apply those pep-
tides to in vitro selection of hybridomas for mAbs, the
cells or recipient animals produce a variety of Abs, most
of which react to a limited number of irrelevant targets,
often molecules that are widely distributed on cell sur-
faces, cytoplasm or nuclei, and are widely cross- reacting
as well [15]. Consequently, induction of Abs to specific
epitopes of interests is a rare or very rare event. It ap-
pears that it will be necessary to inhibit the cellular re-
sponse to cross-reacting epitopes to favor the possible
selection of one or a few epitopes of interest. These ob-
servations raise the question: How does competition be-
tween epitopes serve as an impediment to selection of
these epitopes of functional interest? The best strategies
for favoring responses of interest and inhibiting the
irrelevant responses remain a large challenge, not only
in immunity to infection but also against infection-
associated cancers and in auto-immunity. Thus, it ap-
pears that the immunogenicity of an Ag is essential for
the induction of an immune response but apparently not
sufficient to achieve effective immunity.
What is optimal Ag presentation?
As has been mentioned above, the central issue of pep-
tide immunogenicity is Ag presentation. At a simplistic
level, the capacity for an Ag to be presented to a reactive
lymphocyte can be thought of as the ability of an HLA
molecule to replace the “house-keeping” peptide by a
short (8-20) AA sequence from the foreign Ag that
matches and complements the Ag binding groove on the
HLA molecule [16]. The AA sequence is immobilized
within the HLA groove by physicochemical bonds and is
available to bind the corresponding TcRs on T lympho-
cytes. Ag presentation requires export of the HLA mol-
ecule bound to the peptide to the surface of the APC
surface. The constraints on Ag presentation are, thus,
the presence of APCs at the site of pathogen entry, the
ability of the pathogen to be degraded into AA se-
quences suitable for HLA binding, and the frequency of
HLA molecules (types or “species”) capable of binding
to the AA peptide molecule. There has been consider-
able progress in our understanding of the Ag presenta-
tion process since the discovery of MHC restriction, but
much of our modeling of human Ag presentation de-
rives directly from models of H2 (mouse MHC) mole-
cules, in which Ags appear to be more stringently
restricted to H2 types than perhaps occurs in humans
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is to select candidate vaccine Ags that are less HLA re-
stricted and able to bind a broad spectrum of common
HLA types. In developing vaccines for infectious dis-
eases, the goal is induce effective immunity in more in-
dividuals through Ags selected for optimal presentation,
providing the best chance for a protective response to a
subset of Ags. Paradoxically, Ags from infectious patho-
gens that are not well suited for peptide degradation and
for Ag presentation possess a selective advantage allow-
ing their escape from immune surveillance [18].
In contrast to vaccines, when foreign tissues are
injected or implanted into humans for therapy (blood,
cells, organs, biologics) the goal is to avoid accidental
binding of donor-derived Ags with recipient HLA mole-
cules that subsequently present to T or B cells and in-
duce an immune response resulting in an undesirable
alloimmunization and rejection [19]. In this setting,
strength of immunogenicity is inversely related to thera-
peutic utility, and the principles applied to the selection
of antigenic targets are the converse of those described
above for infectious pathogens, The questions raised
above regarding the crucial role of Ag presentation as a
determinant of immunogenicity are only a few of many
unresolved issues in our understanding of immunogen-
icity. A better understanding of these determinants of
immunogenicity will undoubtedly facilitate the transla-
tion of rational immunologic approaches to vaccinology
and transplantation.
What is the optimal cellular environment for
facilitating and supporting Ag-reactive (formerly
named specific) T and B cells?
Epitope recognition and ligation of an antigenic deter-
minant to the specific TcR is the defining step of the
adaptive immune response, since this step licenses the
epitope as an “Ag”, but it is not, in itself, sufficient to
trigger an immune response. A number of downstream
events, such as APC/T cell co-ligation, formation of the
immunological synapse, immune effector cell activation
and differentiation are equally necessary for the immune
response to proceed. Two other sets of molecules play
crucial roles: 1) cell adhesion molecules and 2) soluble
cytokines. Adhesion molecules are expressed in a re-
stricted manner on APCs and T cells and are required,
partly because the tissue environment does not favor op-
timal immunological synapse formation. Cytokines have
diverse functions in autocrine, paracrine and exocrine
pathways. This may be the reason that the route of vac-
cines is so important [20].
The immunological environment in which the Ag in-
teracts with immune cells appears to be particularly crit-
ical in mucosal immune responses [21,22]. There are
four major issues that have become apparent in thecontext of mucosal immunity: the route of entry for an
infectious agent; competition with or ignorance of the
microbiota (the local microbial flora) in the environ-
ment; the scope of local physiological inflammation; and
local immune system tools available to the host to re-
spond to the invading Ag, such as the diffuse and orga-
nized secondary lymphoid tissues and, in the context of
a chronic inflammatory response, tertiary lymphoid tis-
sues [23]. Overall, the balance between cytokines and
other immune mediators influence the outcome of the T
cell activation and differentiation program. This response,
in turn, enhances or inhibits the intrinsic immunogenicity
of the stimulus. Although our understanding of the modes
of action of many regulatory cytokines has advanced con-
siderably in recent decades, much needs to be learned
about the differences in cytokine environments induced
by different classes of Ags and in different diseases, and
how the environment affects the efficiency and strength of
the resulting immune response.
What drives isotype switching? Why is it
necessary? And what makes an antibody
“protective”?
For decades it has been known that the efficiency of Abs
is affected by the nature of the constituent immuno-
globulin (Ig) of the Ab. There are principally two reasons
for this conclusion. Firstly, the nature of the Ag alters
the heavy (H) chain class/subclass of the Ig that is in-
duced in responding B cells. Investigations using parasite
Ags revealed the role of Ag in biasing the formation of
the induced Abs into distinct subclasses, in a non-
random manner [24]. The role of epitopes in clonal im-
printing of Ab responses has been addressed by analysis
of the light (L) chains in malaria and HIV infections [25,
26], but further elucidation of the phenomenon in other
infections is needed for an understanding of how
generalizable these observations are to other classes of
Ags and infectious diseases. Secondly, the structure of Ig
(H chain/class and subclass) influences not only the bio-
logical properties of the Ab such as the capacity to bind
FcRs and CRs, etc., but also the ability of the Ig/Ab to
bind targets (i.e. the antigenic epitopes) [27]. Indeed, the
number of H domains, S-S bonds and glycosylation
affect the conformation to the Ig backbone making it,
for example, more flexible (IgG3) or rigid (IgG1). In
addition, Ig conformation also influences the half-life,
distribution, and vulnerability of an Ab to catabolic deg-
radation. Studies in malaria-infected populations re-
vealed that IgG1 (Igs with a long half-life) were less
efficient than IgG3 (with a short half-life) targeting the
very same epitopes [28]. Cytokines and environment also
critically influence the nature of the H chain isotype.
Unfortunately, little knowledge has been added in re-
cent years to what was known 10 years ago in this area
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fluence of the L chains on the strength of the immune
response. What we know suggests that strategies to en-
hance or favor IgG3 responses to a peptide Ag rather
than IgG1 would likely be preferable for Ags with higher
immunogenicity. However, to date, it has been particu-
larly difficult to engineer IgG3 responses in a vaccine
setting [29]. Glycosylation of the Fc fragment of anti-
bodies is also likely to play an important role in Ab-
associated immunity, possibly in determining whether
the responses are protective or pathogenic [30]. This is,
therefore, an area of current interest and investigation
because of the probable role in antibodies function
(through complement activation and FcR affinity).
In addition to MHC restriction, that has been dis-
cussed above, variations in other genes are also likely to
influence the immune response to Ags as well as Ag
presentation (for example, with Plasmodium Ags [31]);
however, much remains unknown about which classes of
genes affect the nature of immune responses to patho-
gens and vaccine Ags.
Why is a long-term memory response less robust
when elicited by engineered peptides than by
wild-type pathogen-derived Antigens?
Recent epidemiologic studies reveal several of the vac-
cines used in the expanded program on immunization
(EPI, designed by the World Health Organization) re-
quire a boost during the teenage years or in young adult-
hood because of waning long term immunity. Examples
of such vaccines include measles and pertussis [32]. One
explanation proposed for these observations is that, with
the successful application of measles or pertussis vaccin-
ation programs, establishment of herd immunity is no
longer occurring by natural boosting of immunity from
exposure to circulating pathogens that were prevalent in
unimmunized populations. In fact, declining protection
rates are significant enough to have spurred a call for a
revision of the vaccination schedule, adding booster im-
munizations during the teen years or young adulthood.
Boosts in immunity using re-vaccination is an estab-
lished strategy to maintain immunity for several com-
monly used vaccines (e.g. tetanus toxoid, in which case
immunization is recommended every 10 years), particu-
larly where sufficient coverage of the population has
been achieved to prevent exposure to natural infections.
These observations regarding the decline in immunity
over time have focused attention on the nature of long-
term immunity to vaccine Ags, and prompted debate
and reconsideration of optimal schedules for routine im-
munizations. In short, these observations raise important
questions about the immunogenicity of synthetic vaccines
in contrast to complex, multi-epitope vaccines that have
been traditionally derived from inactivated pathogens orattenuated wild- type infectious agents. The failure of syn-
thetic vaccines to generate sustained memory implies sub-
optimal immunogenicity and highlights the need for
better understanding of immunogenicity in relation of Ag
configuration or formulation.
Is there any other business?
This short review has essentially addressed the issue of
the quality of the Ab response, and not much its quanti-
tative related issues, apart the possible overstimulation
of the immune system—the extrafollicular pathway—by
non- protein Ags, leading to the production of polyreac-
tive Abs, that often useful for assisting if not clearing an
infection [33]. The issue of excess of reactant in the Ag/
Ab complex relates to a very old debate in immunology,
with the prozone effect; it is presently revived because of
newer tests that are complicated by this phenomenon
[34]. This enlightens the issue that Ags that elicit very
strong Ab responses will not lead to protection through
the presence of too much specific Ag (as seen in malaria,
for example [35]).
Further—though this exceeds the present topics—no-
vel approaches are urgently needed to increase immuno-
genicity of novel vaccine candidates. Indeed, ways to
improve already existing vaccines or to “create” new vac-
cines encompass: -i) the vaccinated own parameters
(capacity to raise a suitable response, meaning that the
immune system is mature enough and the nutritional
status correct); ii) the nature of the epitopes (chemistry)
plus the route, the presentation and the circumvention
of the HLA restriction, the adjuvanticity or the delivery
vehicles, etc. The genome sequencing era, the existence
of microarrays, and the availability of new animal models
allowed to revisit the search for vaccine candidates, that
lead to protective Abs. However, the characteristics of
long-lasting, protective responses have evolved overtime
along with the identification of novel targets for Ags and
the revisit of correlates for protection. This challenge is
vivid in several fields and particularly in the quest for
vaccines against parasitic infections such as malaria [36].
Concluding remarks
In summary, immunogenicity is central to the acquisi-
tion and maintenance of natural immunity to infectious
agents. In this context, natural immunity refers to the
immune state resulting from natural infections vis a vis
immunization with synthetic Ags that mimic pathogen-
derived Ags. Immunogenicity is also crucial for acquisi-
tion and maintenance of long-lived and effective post-
vaccine immunity to infectious pathogens. However, if
immunogenicity is a property of Ags directly associated
with the pathogen, the ability to engineer epitopes has
provided tools to enhance or inhibit the immunogenicity
of these natural Ags to tailor the response as desired or
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the desired alteration of responses it will be essential to
gain better understanding of the determinants of im-
munogenicity. Recent advances in our knowledge about
Ag structure and processing have given us some insight
in to these determinants. These investigations have lead
us to the realization that, not surprisingly, in addition to
properties of the Ags themselves, these determinants in-
clude host factors that establish the optimal tissue and
lymph node environments for efficient activation of the
innate and adaptive immune response. However, the
mechanisms by which the determinants confer immuno-
genicity remain to be elucidated. Knowledge of these
mechanisms is particularly important in the field of vac-
cinology. Vaccine candidates are selected on the basis of
being major epitopes that elicit a robust, protective, im-
mune response. To identify such epitopes it will be ne-
cessary to understand the determinants of an optimal
immunological response. Thus a better understanding of
the nature of immunogenicity will be essential for us to
adopt rational approaches to the design of vaccines for
cancers and for the major infectious disease.
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